Bruce D. Cheson, MD, FACP; John M. Bennett, MD; Kanti R. Rai, MD; Michael R. Grever, MD; Neil E. Kay, MD; Martin M. Oken, MD; Charles A. Schiffer, MD; Michael J. Keating, MD; David H. Boldt, MD; San ford J. Kempin, MD; Kenneth A. Foon, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: The International Working Group on Chronic Lymphocytic Leukemia (1) recently presented its recommendations for the design of clinical trials. There has clearly been a need for standardized criteria for eligibility, response, and toxicity to make published data more interpretable, to allow for the accurate identification of pilot regimens of sufficient interest for testing in large-scale comparative trials, and to minimize the arbitrary nature of dose modifications. Interpretation of results of clinical trials has been complicated by the use of two different staging systems, the Rai (2) and the Binet (3). In 1981, the International Working Group proposed
Cheson BD, Bennett JM, Rai KR, et al. Chronic Lymphocytic Leukemia: Recommendations. Ann Intern Med. 1989;110:664–665. doi: https://doi.org/10.7326/0003-4819-110-8-664
Download citation file:
Published: Ann Intern Med. 1989;110(8):664-665.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use